Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05142813
Other study ID # Sepsis_001
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date May 2022
Est. completion date December 2023

Study information

Verified date March 2022
Source mProbe Inc.
Contact James Schilling
Phone 650479198
Email admin@mprobe.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

A case-control cohort study to develop and validate the performance of a whole blood gene expression test to distinguish sepsis infection from uninfected systemic inflammatory response syndrome cases in symptomatic adults and children without comorbidities.


Description:

The purpose of this prospective, non-interventional study is to develop and validate a blood gene expression test for diagnosing the cause of sepsis in adults and children with symptoms of infection. Sepsis affects 31.5 million people globally leading to 5.3 million deaths each year. Sepsis is particularly harmful to immunodeficient patients undergoing cancer therapy with 3.7 percent to 6.4 percent of cancer patients diagnosed with sepsis in the US in their first year after cancer diagnosis. Current tests to diagnose the infectious cause of sepsis rely on blood cultures which takes 24-48 hours to complete; leading to delays in early treatment critical to reduce the risk of developing sepsis shock and possibly death. In addition, around 50 percent of severe sepsis cases are culture negative, confounded acute infections not detected in the blood, by viral infection or uninfected patients exhibiting systemic inflammatory response syndrome (SIRS). Since sepsis often progresses to sepsis shock within 72 hours, suspected sepsis cases are usually immediately treated with antibiotics until results from testing distinguish the cause of symptoms. This leads to the over-use of antibiotics and delays appropriate treatment for those without bacterial infection or un-infected SIRS. A quick and accurate diagnostic blood test may enable early discrimination of the cause of sepsis resulting in faster more appropriate treatments and reduced sepsis complications and death. The study will collect blood samples from participants presenting symptoms of acute infection, without co-morbidities and follow symptom severity and mortality for 28 days.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 1100
Est. completion date December 2023
Est. primary completion date June 2023
Accepts healthy volunteers
Gender All
Age group 90 Days to 85 Years
Eligibility Criteria: Inclusion Criteria: - Clinical suspicion of an acute infectious disease - Presence of at least ONE of the following: 1. Temperature = 38°C or Temperature = 36°C 2. Heart rate > 90 bpm 3. Respiratory rate > 20/min 4. Self reported fever/chills - Symptom duration = 7 days Exclusion Criteria: - Received antibiotics or antivirals in the past 2 weeks. - Previous infection in previous 2 weeks - Primary or secondary immunodeficiency - Proven or suspected HIV, hepatitis B or hepatitis C infection - Current immune-suppressive or immune-modulating treatment - Active hematological malignancy - Other illnesses that affect life expectancy

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Diagnostic Test: Blood specimen collection
Diagnostic Test: Blood specimen collection Study samples must be collected within before treatment with antibiotics or antivirals.

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
mProbe Inc. The Second Afliated Hospital of Southern University of Science and Technology

Outcome

Type Measure Description Time frame Safety issue
Primary Diagnosis of underlying cause of sepsis infection The sensitivity and specificity of the assay in differentiating bacterial from viral infection. 1 month
Secondary Diagnosis of underlying cause of acute infection symptoms The sensitivity and specificity of the assay in differentiating infectious and non-infectious disease. 1 month
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05095324 - The Biomarker Prediction Model of Septic Risk in Infected Patients
Completed NCT02714595 - Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens Phase 3
Completed NCT03644030 - Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
Completed NCT02867267 - The Efficacy and Safety of Ta1 for Sepsis Phase 3
Completed NCT04804306 - Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
Recruiting NCT05578196 - Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections. N/A
Terminated NCT04117568 - The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
Completed NCT03550794 - Thiamine as a Renal Protective Agent in Septic Shock Phase 2
Completed NCT04332861 - Evaluation of Infection in Obstructing Urolithiasis
Completed NCT04227652 - Control of Fever in Septic Patients N/A
Enrolling by invitation NCT05052203 - Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
Terminated NCT03335124 - The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock Phase 4
Recruiting NCT04005001 - Machine Learning Sepsis Alert Notification Using Clinical Data Phase 2
Completed NCT03258684 - Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock N/A
Recruiting NCT05217836 - Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
Completed NCT05018546 - Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery N/A
Completed NCT03295825 - Heparin Binding Protein in Early Sepsis Diagnosis N/A
Not yet recruiting NCT06045130 - PUFAs in Preterm Infants
Not yet recruiting NCT05361135 - 18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia N/A
Not yet recruiting NCT05443854 - Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) Phase 3